China’s Hope Medicine has signed a world-wide exclusive license agreement with Bayer on the development and commercialization of a human antibody targeting the PRL receptor for the treatment of male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. 8 April 2019
Sweden’s Gesynta Pharma has raised 6 million euros ($6.7 million) to help develop its lead candidate GS-248. The firm is aiming to take the therapy into Phase II trials in 2020. 5 April 2019
Lipocine says it has filed suit against Clarus Therapeutics in the US District Court (Delaware) alleging that Clarus' Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism, infringes six of Lipocine's US patents. 4 April 2019
Israeli immunotherapy company Enlivex Therapeutics has raised nearly $5.4 million in a private offering, along with the completion of its merger with Bioblast Pharma. 2 April 2019
Dutch biotech Micreos has secured 30 million euros in funding to advance the development of its endolysin technology, which it claims is ‘set to replace antibiotics’. 29 March 2019
The US Food and Drug Administration is making available a final guidance titled Pediatric Information Incorporated into Human Prescription Drug and Biological Product Labeling. 29 March 2019
Japan’s Mitsubishi Tanabe has been awarded a grant of 192 million yen ($1.7 million) by the Global Health Innovative Technology Fund (GHIT Fund), to help develop novel antimalarial drugs. 29 March 2019
ProQR Therapeutics, a Dutch company developing RNA medicines for severe genetic rare diseases, has spun out its dystrophic epidermolysis bullosa (DEB) activities into the newly-formed company, Wings Therapeutics. 28 March 2019
Prevail Therapeutics has raised $50 million in a series B financing round. The company is focused on developing AAV-based gene therapies for neurodegenerative disorders. 28 March 2019
A new Shanghai-based facility owned by WuXi AppTec subsidiary STA Pharmaceutical has passed its first GMP inspection by the European Medical Products Agency (MPA). 28 March 2019
Eli Lilly has agreed terms for a global licensing and research collaboration with ImmuNext, focused on the study of a novel preclinical target with potential in autoimmune diseases. 27 March 2019
Shanghai-based Abbisko Therapeutics has raised $42 million in a series B financing round, led by local investors Qiming Venture Partners, with money also from Lilly Asia Ventures and others. 26 March 2019
Hookipa Pharma has submitted a prospectus for an $86 million initial public offering (IPO) on the Nasdaq stock exchange, weeks after announcing it had raised nearly $40 million in a series D round. 26 March 2019
Privately-held oncology specialist Aprea Therapeutics has recruited Eyal Attar to the role of senior vice president and chief medical officer. 25 March 2019
STA Pharmaceutical, a subsidiary of China’s WuXi AppTec, and Beta Pharma, a biotech company focusing on innovative drug discovery and development in oncology, announce a strategic partnership. 22 March 2019
London-listed Diurnal says it will submit its Orphan Drug-designated Alkindi (hydrocortisone) for regulatory approval in the USA towards the end of this year. 20 March 2019
California’s NapaJen Pharma has inked an R&D deal with Astellas Pharma for the discovery and development of novel oligonucleotide therapeutics. 19 March 2019
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024